Open Label, Multicentre Study, Evaluating the Safety, Tolerability, Efficacy, Compliance and Acceptability of Alkalising Treatments at Long-term in Patients With Cystinuria

B14CS

This is an open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and acceptability of alkalising treatments at long-term in patients with cystinuria.

2024-05-01

2025-06-01

2025-08-01

Withdrawn

Early phase I

Inclusion Criteria: * For ADV7103 cohort: 1. Patient who has participated to and completed the previous B12CS Study or B13CS Study. 2. Patient for whom the safety and tolerability of ADV7103 were satisfactory during B12CS Study or B13CS Study. 3. Female patient of childbearing potential (defined by the Clinical Trial Facilitation Group (CTFG) as woman fertile, following menarche until becoming post-menopausal unless permanently sterile\*) using an acceptable effective birth control method\*\* and having a negative pregnancy test at the inclusion, or a woman postmenopausal\*\*\* or a woman surgically sterilized\*. 4. Patient and/or parents or legal representative(s) who is(are) willing and able to participate in the study, to understand and to comply with study procedures for the entire length of the study. 5. Patient or parents or legal representative(s) who has(have) provided a signed written informed consent. 6. Patient of ≤17 Patient of ≤17 years of age for whom the assent has been collected or has been tried to be collected. 7. Patient who is affiliated to a social health insurance system and/or in compliance with the recommendations of the national law in force relating to biomedical research. For Standard of Care cohort: 1. Patient who has a diagnosis of cystinuria based on medical diagnosis (at least one previous or current episode of calculus of cystine, and/or one previous or current episode of cystine crystalluria) or on genetic diagnosis (only for patients of Subset 4). 2. Patient treated with an alkalising treatment at a well-adapted dose (defined as a daily dose deemed by the investigator aiming to maintain overtime urinary pH value ≥ 7.0 and/or compatible with an acceptable safety profile and/or patient's constraints or compliance). 3. Patient male or female, including child aged between 6 months and 17 years old and adult aged ≥ 18 years old up to 70 years old. 4. Female patient of childbearing potential (defined by the Clinical Trial Facilitation Group (CTFG) as woman fertile, following menarche until becoming post-menopausal unless permanently sterile\*) using an acceptable effective birth control method\*\* and having a negative pregnancy test at the inclusion, or a woman postmenopausal\*\*\* or a woman surgically sterilized\*. 5. Patient and/or parents or legal representative(s) who is(are) willing and able to participate in the study, to understand and to comply with study procedures for the entire length of the study. 6. Patient or parents or legal representative(s) who has/have provided a signed written informed consent. 7. Patient of ≤17 years of age for whom the assent has been collected or has been tried to be collected. 8. Patient who is affiliated to a social health insurance system and/or in compliance with the recommendations of the national law in force relating to biomedical research. Exclusion Criteria: * For ADV7103 cohort: 1. Patient who has not participated to B12CS study or B13CS study 2. Patient for whom any safety issue could contraindicate her/his participation to the extension study For Standard of Care cohort: 1. Patient that is receiving the second line therapy -- cystine chelating agents (sulfhydryl compounds). 2. Patient who presents kalaemia \> 5.0 mmol/L. 3. Patient who presents a moderate or severe renal impairment (estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m2 according to Schwartz formula for the children and both MDRDs and CKD-EPI for adults). 4. Patient who presents - barring the study disease - any previous or concurrent medical condition or any laboratory or clinical findings or any other condition that in the opinion of the investigator would be negatively affected by the study product or that would affect the study product or that precludes his participation, e.g. uncontrolled diabetes mellitus, adrenal insufficiency, cardiac impairment, repeated infections, metabolic alkalosis, chronic diarrhoea. 5. Female patient who is pregnant or breast-feeding. 6. Patient who cannot stop potassium sparing diuretics (e.g. antagonists of aldosterone as such spironolactone, canrenoate and eplerenone, amiloride, triamterene), angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, tacrolimus, potassium desodic salts. 7. Patient who received any medication that could interfere with the study treatment within 4 weeks before the inclusion in the study, including angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, tacrolimus, potassium desodic salts, antibiotics. 8. Patient who received potassium sparing diuretics 6 weeks before the inclusion in the study. 9. Patient who is admitted to hospital in emergency settings. 10. Patient who participated in a clinical trial within the last 3 months before enrolment. 11. Patient who is at risk of non-compliance in the judgment of the investigator. 12. Patient who could present any other condition, which in the opinion of the investigator, would preclude participation in the study. 13. Patient who cannot be contacted in case of emergency. 14. Patient under any administrative or legal supervision.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}

2024-03-12